Glycocalyx Supplement Lowered Heart Failure Risk Markers in Type 2 Diabetics, Measured by Urinary Peptides

Glycocalyx-mimetic supplementation significantly reduced heart failure risk scores (HF2) by a mean of -0.58 (95% CI: -0.83 to -0.33, adjusted p<0.001) as measured by urinary peptidomic classifiers. The supplement altered 17 urinary peptides, primarily decreasing collagen-derived fragments, suggesting improved extracellular matrix turnover. Coronary artery disease (CAD160) and chronic kidney disease (CKD273) risk scores were unchanged. Neither the fasting-mimicking diet nor placebo produced meaningful changes in any classifier.

This was a follow-up analysis of a prior placebo-controlled trial. Forty-four South-Asian Surinamese adults with type 2 diabetes were randomly allocated to 12 weeks of daily glycocalyx-mimetic capsules (n=18), placebo (n=14), or a 5-day fasting-mimicking diet repeated every 4 weeks (n=12). Urine samples at baseline and week 12 were analyzed using capillary electrophoresis-mass spectrometry. Three pre-validated peptide classifiers scored risk for heart failure, coronary artery disease, and chronic kidney disease.

Type 2 diabetes dramatically increases cardiovascular risk. This study shows a dietary supplement can measurably improve a validated biomarker of heart failure risk — using cutting-edge peptidomic technology to detect changes at the molecular level. The glycocalyx (the protective lining of blood vessels) is damaged in diabetes, and this is one of the first interventional studies showing it can be therapeutically targeted with a supplement.

The glycocalyx — a fragile sugar-protein layer coating blood vessel walls — is increasingly recognized as critical for vascular health and is damaged early in diabetes. This study represents a new therapeutic strategy: rather than treating downstream cardiovascular complications, repair the glycocalyx itself. The use of urinary peptidomics as a monitoring tool is also innovative, offering a non-invasive way to track vascular health changes at the molecular level.

Small sample size of only 44 participants across three groups. The study population was limited to South-Asian Surinamese adults, which may limit generalizability. Only urinary peptide biomarkers were measured — no hard clinical endpoints like actual heart failure events. CAD and CKD risk scores did not change, limiting the scope of cardiovascular benefit. The 12-week duration may be too short to detect all effects.